Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer? - ScienceDirect
Frontiers | The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
PDL2 monoclonal antibody (7C7) - ENZ-ABS697 - Enzo Life Sciences
Genes | Free Full-Text | High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
PD-L2 Detection Set - Cat. No. RF16020 | ProSci
AlphaLISA Human PD-1/PD-L2 Binding Kit, 500 Assay Points | PerkinElmer
Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action | Immunotherapy
AlphaLISA Human PD-1/PD-L2 Binding Kit, 500 Assay Points | PerkinElmer
Regulation of T cell activation and tolerance by PDL2 | PNAS
PD-1/PD-L1+PD-L2 signaling pathway. PD-1, programmed death receptor 1;... | Download Scientific Diagram
Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations - Physical Chemistry Chemical Physics (RSC Publishing)
Anti-Human CD273/PDL2 (24F.10C12)-172Yb—100 Tests
PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy | Journal for ImmunoTherapy of Cancer
PD-1/PD-L1 inhibitors treatment in lung cance | EurekAlert!
Role of PD‐L1 and PD‐L2 in allergic diseases and asthma - Singh - 2011 - Allergy - Wiley Online Library
Recombinant Human PD-L2 protein (Active) (ab283481) | Abcam
PD-L1 and PD-L2 mRNA Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-treated Non-small Cell Lung Cancer < Yale School of Medicine
Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology - ScienceDirect
Human PD-L2/B7-DC Antibody AF1224: R&D Systems
PathPlus™ PD-L2 / PDCD1LG2 / CD273 Monoclonal Antibody Mouse | LSBio
PD-L2: A Viable Prognostic Biomarker in Prostate Cancer – Consult QD
JAK-STAT pathway deregulation and regulation of PDL1 and PDL2... | Download Scientific Diagram
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy | British Journal of Cancer
